SK50102006A3 - Spôsob prípravy kryštalického polymorfu inhibítora zrážania krvných doštičiek - Google Patents
Spôsob prípravy kryštalického polymorfu inhibítora zrážania krvných doštičiek Download PDFInfo
- Publication number
- SK50102006A3 SK50102006A3 SK5010-2006A SK50102006A SK50102006A3 SK 50102006 A3 SK50102006 A3 SK 50102006A3 SK 50102006 A SK50102006 A SK 50102006A SK 50102006 A3 SK50102006 A3 SK 50102006A3
- Authority
- SK
- Slovakia
- Prior art keywords
- solvent
- mixture
- clopidogrel
- type
- solvents
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims description 24
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 title 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 title 1
- 229940127218 antiplatelet drug Drugs 0.000 title 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 title 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 64
- 229950010477 clopidogrel hydrogen sulphate Drugs 0.000 claims abstract description 64
- FDEODCTUSIWGLK-UHFFFAOYSA-N hydrogen sulfate;hydron;methyl 2-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridin-5-yl)acetate Chemical compound OS(O)(=O)=O.C1CC=2SC=CC=2CN1C(C(=O)OC)C1=CC=CC=C1Cl FDEODCTUSIWGLK-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000002904 solvent Substances 0.000 claims abstract description 62
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims abstract description 29
- 229960003009 clopidogrel Drugs 0.000 claims abstract description 29
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims abstract description 29
- 239000002244 precipitate Substances 0.000 claims abstract description 19
- 239000000725 suspension Substances 0.000 claims abstract description 13
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- 238000005406 washing Methods 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000010 aprotic solvent Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- -1 6,7-dihydro-4 H -thieno [3,2-c] pyridin-5-yl Chemical group 0.000 claims description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 239000012454 non-polar solvent Substances 0.000 claims description 3
- 239000003880 polar aprotic solvent Substances 0.000 claims description 3
- 239000003586 protic polar solvent Substances 0.000 claims description 3
- 239000011877 solvent mixture Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000013078 crystal Substances 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 239000012296 anti-solvent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- FDEODCTUSIWGLK-RSAXXLAASA-N clopidogrel sulfate Chemical compound [H+].OS([O-])(=O)=O.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl FDEODCTUSIWGLK-RSAXXLAASA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- LFHDINMNPBZSNH-UHFFFAOYSA-N C1N(OC(=O)C)CCC2=C1C=CS2 Chemical compound C1N(OC(=O)C)CCC2=C1C=CS2 LFHDINMNPBZSNH-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- UCTLHLZWKJIXJI-LXIBVNSESA-N [(3s,8r,9s,10r,13s,14s)-17-chloro-16-formyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(Cl)=C(C=O)C[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 UCTLHLZWKJIXJI-LXIBVNSESA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- QZDWODWEESGPLC-UHFFFAOYSA-N pyridin-3-yl acetate Chemical compound CC(=O)OC1=CC=CN=C1 QZDWODWEESGPLC-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0302028A HU0302028D0 (en) | 2003-07-02 | 2003-07-02 | Process for the production of crystalline polymorphous form of an anticoagulant agent |
| HU0401272A HU226773B1 (en) | 2004-06-23 | 2004-06-23 | Process for the production of clopidogrel hydrogensulfate polymorph 1 |
| PCT/HU2004/000070 WO2005003139A1 (en) | 2003-07-02 | 2004-06-30 | Process for the preparation of crystalline polymorph of a platelet aggregation inhibitor drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK50102006A3 true SK50102006A3 (sk) | 2006-05-04 |
Family
ID=89985327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK5010-2006A SK50102006A3 (sk) | 2003-07-02 | 2004-06-30 | Spôsob prípravy kryštalického polymorfu inhibítora zrážania krvných doštičiek |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070142637A1 (pl) |
| EP (1) | EP1644381B1 (pl) |
| JP (1) | JP4681545B2 (pl) |
| KR (1) | KR101155679B1 (pl) |
| CN (1) | CN1812993B (pl) |
| AT (1) | ATE461201T1 (pl) |
| BG (1) | BG109429A (pl) |
| CA (1) | CA2530449C (pl) |
| CZ (1) | CZ200641A3 (pl) |
| DE (1) | DE602004026059D1 (pl) |
| EA (1) | EA010684B1 (pl) |
| PL (2) | PL378710A1 (pl) |
| SK (1) | SK50102006A3 (pl) |
| WO (1) | WO2005003139A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029459T2 (en) * | 2004-04-19 | 2017-02-28 | Krka Tovarna Zdravil D D Novo Mesto | Methods for the Preparation of Polymorph Form I of Clopidogrel Hydrogen Sulphate |
| EP1902058A2 (en) * | 2005-07-12 | 2008-03-26 | RPG Life Sciences Limited | A process for preparation of methyl-(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4h)-acetic acid methyl ester or salts thereof having higher chiral purity and products thereof |
| KR20080055860A (ko) * | 2006-08-03 | 2008-06-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 클로피도그렐 바이설페이트의 제조 방법 |
| WO2011010318A1 (en) * | 2009-07-23 | 2011-01-27 | Praveen Laboratories Private Limited | Process for the preparation of clopidogrel polymorphous form 1 using seed chrystals |
| CN102070648A (zh) * | 2010-12-07 | 2011-05-25 | 天津红日药业股份有限公司 | I型硫酸氢氯吡格雷的制备方法 |
| CN102702224A (zh) * | 2012-06-25 | 2012-10-03 | 山东齐都药业有限公司 | I型硫酸氢氯吡格雷的制备方法 |
| CN107337683B (zh) * | 2017-08-16 | 2019-08-16 | 中荣凯特（北京）生物科技有限公司 | 一种噻吩并吡啶类衍生物硫酸氢盐的晶型ⅱ及其制备方法和应用 |
| CN113121559B (zh) * | 2019-12-31 | 2023-08-29 | 惠州信立泰药业有限公司 | 一种高堆密度的ii型硫酸氢氯吡格雷球形结晶及制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| FR2779726B1 (fr) * | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
| ATE349451T1 (de) * | 2001-01-24 | 2007-01-15 | Cadila Healthcare Ltd | Verfahren zur herstellung von clopidogrel |
| GB0125708D0 (en) * | 2001-10-26 | 2001-12-19 | Generics Uk Ltd | Novel compounds and processes |
| AU2002366383B2 (en) * | 2001-12-18 | 2007-06-14 | Teva Pharmaceutical Industries Ltd. | Polymorphs of clopidogrel hydrogensulfate |
-
2004
- 2004-06-30 EP EP04743729A patent/EP1644381B1/en not_active Expired - Lifetime
- 2004-06-30 CA CA2530449A patent/CA2530449C/en not_active Expired - Fee Related
- 2004-06-30 CZ CZ20060041A patent/CZ200641A3/cs unknown
- 2004-06-30 PL PL378710A patent/PL378710A1/pl not_active Application Discontinuation
- 2004-06-30 EA EA200600138A patent/EA010684B1/ru not_active IP Right Cessation
- 2004-06-30 DE DE602004026059T patent/DE602004026059D1/de not_active Expired - Fee Related
- 2004-06-30 JP JP2006516497A patent/JP4681545B2/ja not_active Expired - Fee Related
- 2004-06-30 CN CN2004800181228A patent/CN1812993B/zh not_active Expired - Fee Related
- 2004-06-30 SK SK5010-2006A patent/SK50102006A3/sk unknown
- 2004-06-30 WO PCT/HU2004/000070 patent/WO2005003139A1/en active Application Filing
- 2004-06-30 KR KR1020067000012A patent/KR101155679B1/ko not_active IP Right Cessation
- 2004-06-30 AT AT04743729T patent/ATE461201T1/de not_active IP Right Cessation
- 2004-06-30 US US10/563,133 patent/US20070142637A1/en not_active Abandoned
- 2004-06-30 PL PL04743729T patent/PL1644381T3/pl unknown
-
2006
- 2006-02-02 BG BG109429A patent/BG109429A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2530449C (en) | 2010-03-23 |
| EA010684B1 (ru) | 2008-10-30 |
| BG109429A (en) | 2006-10-31 |
| JP2007516167A (ja) | 2007-06-21 |
| CZ200641A3 (cs) | 2006-05-17 |
| EP1644381A1 (en) | 2006-04-12 |
| WO2005003139A1 (en) | 2005-01-13 |
| CN1812993A (zh) | 2006-08-02 |
| JP4681545B2 (ja) | 2011-05-11 |
| KR101155679B1 (ko) | 2012-06-13 |
| EP1644381B1 (en) | 2010-03-17 |
| ATE461201T1 (de) | 2010-04-15 |
| KR20060026119A (ko) | 2006-03-22 |
| EA200600138A1 (ru) | 2006-08-25 |
| DE602004026059D1 (de) | 2010-04-29 |
| PL378710A1 (pl) | 2006-05-15 |
| PL1644381T3 (pl) | 2010-08-31 |
| CN1812993B (zh) | 2011-06-29 |
| US20070142637A1 (en) | 2007-06-21 |
| CA2530449A1 (en) | 2005-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1740593B1 (en) | Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i | |
| EP1656381B1 (en) | Crystallisation of solid forms of clopidogrel addition salts | |
| WO2005012300A1 (en) | A novel process for the manufacture of (+)-(s)-clopidogrel bisulfate form-i | |
| PL196069B1 (pl) | Sposób wytwarzania zasadniczo czystej postaci II olanzapiny | |
| SK50102006A3 (sk) | Spôsob prípravy kryštalického polymorfu inhibítora zrážania krvných doštičiek | |
| EP0733634B1 (en) | Process for preparing a thieno(2,3-B)(1,5) benzodiazepine derivative | |
| SK50942005A3 (sk) | Polymorfy hydrochloridu olanzapínu | |
| WO2006087226A1 (en) | Process for preparing clopidogrel hydrogen sulfate of form i | |
| EA008055B1 (ru) | Кристаллические формы оланзапина и способы их получения | |
| CZ200660A3 (cs) | Zpusob prípravy amorfní formy léciva - inhibitorusrázení krevních desticek | |
| HU226773B1 (en) | Process for the production of clopidogrel hydrogensulfate polymorph 1 | |
| WO2005085256A1 (en) | Isopropanol water solvate of olanzapine | |
| US20090036683A1 (en) | Method for preparing clopidogrel 1,5-naphthalenedisulfonate or hydrate thereof | |
| HU226565B1 (en) | Process for the production of the amorphous form of clopidogrel hydrogen sulfate | |
| PL204250B1 (pl) | Sposób wytwarzania postaci amorficznej wodorosiarczanu klopidogrelu | |
| SI21749A (sl) | Postopek za pripravo polimorfne oblike I klopidogrel hidrogen sulfata | |
| WO2011010318A1 (en) | Process for the preparation of clopidogrel polymorphous form 1 using seed chrystals | |
| SK12852002A3 (sk) | Spôsob výroby clopidogrelu hydrogensulfátu kryštalickej formy I |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB9A | Suspension of patent application procedure |